Ontology highlight
ABSTRACT:
SUBMITTER: Savoia P
PROVIDER: S-EPMC6472057 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
Savoia Paola P Fava Paolo P Casoni Filippo F Cremona Ottavio O
International journal of molecular sciences 20190325 6
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have opened a new era in the treatment of this tumor. Vemurafenib was the first specific kinase inhibitor approved for therapy of advanced melanomas harboring BRAF-activating mutations, followed by dabrafenib and encorafenib. However, despite the excellent results of first-generation kinase inhibitors in terms of response rate, the average duration of the response was short, due to the onset of geneti ...[more]